Goldline Pharmaceutical IPO
Pharmaceuticals • ₹11.61 Cr
Medium risk because:
- 5 material risk factors disclosed in DRHP
- SME listing with thinner post-listing liquidity
- The company is dependent on third-party contract manufacturers for the production of its p…
IPOFins risk score from DRHP risk factors, subscription demand & issue structure
Price Band
₹43
Issue Size
₹11.61 Cr
Open
12 May 2026
Close
14 May 2026
Subscription
770×
IPO Schedule
| Issue Open Date | 12 May 2026 |
| Issue Close Date | 14 May 2026 |
| Listing Date | 18 May 2026 |
About Goldline Pharmaceutical
Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand. The company operates through five product segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness, catering to therapeutic areas including cardiology, diabetology, orthopaedics, paediatrics, gastroenterology, neurology, critical care, and oncology supportive care. Its products are manufactured through contractual arrangements with third-party manufacturers based on the company’s specifications, demand analysis, and market research. Goldline also provides material supply and procurement support services to hospitals and healthcare partners through promoter group entities involved in trading and supply chain operations. The company markets its products through a distribution network consisting of distributors, wholesalers, and retailers. As of March 31, 2025, Goldline maintained contractual arrangements with 15 manufacturers and seven distributors to support its supply chain and operations. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company — Rs 8.9 crore General corporate purposes
Company Details
Founders / Promoters
Mr Amol Mujumdar
Founded
2004
Documents
DRHP / RHP Document (PDF)
View official prospectus →
Investment Analysis
Goldline Pharmaceutical — IPOFins Verdict
QuantitativeDriven by QIB demand at 180.2x and moderate disclosed risk (5/10), Goldline Pharmaceutical listed at a premium of 39.0% to its issue price. SME listings are also thinner and more volatile after listing. The signals lean constructive — still confirm valuation against listed peers and read the DRHP before applying beyond one lot.
- The company operates an asset-light business model by outsourcing manufacturing to third-party manufacturers instead of investing in its own manufacturing facilities. This allows the company to focus
- Goldline Pharmaceutical offers products across five different segments, namely Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These product categories
- The company claims to have established long-term relationships with third-party manufacturers and distributors to support its supply chain operations. As of March 31, 2025, the company maintained cont
- The company claims to follow a demand-driven product selection and inventory planning process based on market surveys, historical inventory analysis, and Intercontinental Medical Statistics (IMS) data
- The company claims to have an established distribution network covering multiple regions through distributors, wholesalers, and retailers. This network supports product availability and market reach a
Score breakdown — what drove this verdict
Moderate risk from DRHP → score +0.0
Institutional subscription → score +2.0
Strong retail interest → score +0.5
Actual listing outcome → score +1.5
SME IPOs have lower liquidity after listing → score −0.5
Base score: 5.0 · Final score = base + all factor adjustments, capped 1–10. Full methodology →
IPOFins Score is a quantitative signal from subscription demand, disclosed risk, and listing data — not investment advice. Not SEBI-registered.
Listing Performance
Issue Price
₹43
Listing Price
₹59.75
Listing Gain/Loss
+38.95%
Listing Date
18 May 2026
Price Since Listing
Returns are measured against the ₹43 issue price.
Listing
₹59.75
+39.0%
1 Week
₹46.26
+7.6%
1 Month
₹43.67
+1.6%
Current
₹38.5
-10.5%
Want to buy this stock?
Trade Goldline Pharmaceutical on the secondary market
FAQ
What is the price band of Goldline Pharmaceutical IPO?
The price band is ₹43 per share with a lot size of 0 shares.
What does Goldline Pharmaceutical do?
Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand. The company operates through five product segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness, catering to therapeutic areas including cardiology, diabetology, orthopaedics, paediatrics, gastroenterology, neurology, critical care, and oncology supportive care. Its products are manufactured through contractual arrangements with third-party manufacturers based on the company’s specifications, demand analysis, and market research. Goldline also provides material supply and procurement support services to hospitals and healthcare partners through promoter group entities involved in trading and supply chain operations. The company markets its products through a distribution network consisting of distributors, wholesalers, and retailers. As of March 31, 2025, Goldline maintained contractual arrangements with 15 manufacturers and seven distributors to support its supply chain and operations. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company — Rs 8.9 crore General corporate purposes
Should I apply for Goldline Pharmaceutical IPO?
Goldline Pharmaceutical listed at ₹59.75 (+39.0% premium to the ₹43 issue price) after 769.6x subscription. IPOFins Score 9/10: Driven by QIB demand at 180.2x and moderate disclosed risk (5/10), Goldline Pharmaceutical listed at a premium of 39.0% to its issue price. SME listings are also thinner and more volatile after listing. The signals lean constructive — still confirm valuation against listed peers and read the DRHP before applying beyond one lot.
Who founded Goldline Pharmaceutical?
Goldline Pharmaceutical was founded by Mr Amol Mujumdar in 2004.